Company Registration Number: 7493363
CRIS CANCER FOUNDATION
A COMPANY LIMITED BY GUARANTEE
(CHARITY No. 1140193)
REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023
ENV45728537-2320-EEAA4WCCDB
0710812024 09.'00 AM UTC

CRIS CANCER FOUNDATION
A COMPANY LIMITED BY GUARANTEE
(CHARITY NO. 1140193)
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023
Index
P*ge
Report of the trust¢¢s
Report of the audiiors
Stateinent of financial activities
10
Balance sheet
Cash flow statcment
12
Notes forniing part of th¢ financial statements
ENV45728537-2320-EEAA49e¥ccDB
0710812024 09..00 AM UTC

CRIS CANCER FOUNDATION
REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2023
The trustecs, who aT¢ also dir¢ctor5 of th¢ charitablc company for the purposes of company law, present
their report along with the financial statements for the year ended J l December 202J.
The financial stateinenis Comply with the Charities Act 201 I, the Coinpanies Act 2006, the Meinordnduin
and Articles of A5socialion, and Accounting and Reporting by Charities.. Siateinent of Recomtnended
Practice applicable to charities preparing their account5 in accordance with the Financial Reporting
Standard in th¢ UK and R¢public of Ireland IFRS 1021.
Objective5 and activities
The objects of CRIS Cancer Foundation ICIUS) are to protect and proinole the health of the public through
supporting research into the nature. causes. diagnosis, prevention, treaimeni and cure of all fom)s of cancer,
including the developmeni of research findings inio practtcal applications foi the pievention, treatment and
cute of cancer and to pmvide inforniaiion and raise ptsblic undersianding of such mat￿1$.
Public benefit
The directors have complied with section 17(51 of the 2011 Charities Att, haV￿g due regard for the Charity
Commi55ion'5 guid8noe on publie ben¢fit when r¢Yiewing th¢ Iru5t's aims and objectives.
Achievements &nd performance
2023 has been an exceptional year for the CRIS Cancer Foundation, as we continue io expand and solidify
our presence in the UK. We recognise that only through dedicated investinenl in research can we hope to
defeai cancer a relentless disease that poses an escalaiing global health challenge.
This year CRIS achieved a total income of £3,010.944, a 680/0 increase over the prev20us year, with a
subsiantial £1.713,L46 invested in research. represeniing a 170/0 increase from last year.
We enhanced our Annual Gala by hosting li ai the prestigious Naruial History Museum in London. This
move, made possible by our sponsors ILJ. O'Brien and Tradeweb. significantly boosted the gala's income.
In addilion to strengthening our Annual Gala. we have been creating altetnative revenue Streams through
consolidating partnetships wilh co4)orations such as AKO Foundation. Goldman Sachs. General Atlantic.
and esiablishin8 new links wilh olheES such as ICE Futures Europe. A key highlight of our Siialegic
expansion in fijndrdising efforts this year was ihe iniToduciion of sorne new dnd divers¢ ev¢tklS. Among
these, the standout was an exceptional gathering featuring the acclaitned soprano Ainhoa Arteta and
Mi¢h¢lin-starred ch¢f Quiqu¢ Dacosta. This unique ev¢nl prov¢d to b¢ our m05t SU¢CCSsful fundraising
activity of the year, aside from th¢ Annual Gala. 0¢￿eroUS7Y supported by Marketaxess, it significantly
boosted our income, d¢monslTating th¢ ¢ff¢¢tiv¢n¢55 of div¢rsifying oui event portlolio in raising funds.
On the research froni. CIUS continues to support leading institulions such as Ihe ICR. Oxford Universiry.
and GOSH. In 2023. we also joined Fight Kids Cancer. a pan-European consortium thai focuses on
paediatric oncology research.
ENV45728537-2320-EEhA4964CCDB
0710812024 09..00 UTC

CRIS CANCER FOUNDATEO
REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2023
Fiindin¥ CRIS Cftneer Foundallt>ll
Thc charity has five principal sources of fimding..
Ball
Year after year, the Annual Gala leaves our team deeply moved by the overwhelining support from our
loyal CRIS community. which includes supporters. prize donors, researchers, doctors, and volunteers.
Thanks to the generosity of our prize donoTS. guests bid on arnazing holiday hoines, excliisive trips,
wondethl fo(NJ expenences, and incredible spotts memorabilia. This year, in the UK, we raised over £2
million in one nigh¢ supported significantly by corporate swnsors R.J. O'Brien and Tradeweb thrgugh
tickei sales, pledges, and auctIons. This event was also celebrated internationally, with parall¢l galas host¢d
by CRIS Spain in Madrid and CRIS France sn Paris.
Fundroising a¢livilEes (non-corporfjte)
Ov¢r 50 Junn¢rs took to the stre¢ts of London for the Royal Parks Half Marathon in aid of the CRIS Cancel
Foundation, including voluntccrs, doctors, scientists, cancer sutvivors. and family tnembets of cancel
patients. Encourdged 31ong rhe way by our amazing volLmteers, our incredible nmner5 tnanaged to rdise
almost £80.000, which Is an increase of 170/D in revenue coinpared to 2022.
CRIS relaunched My Super CRIS Challenge tliis year. one of our most popular initiatives. It provides a fun
and simple way for our cornmunity to sei a New Year's challenge that also serves as a fundraising activity-
Thi5 engaging approach helps u5 raise vital fund5 for CRIS, bringing hope to many patients and families.
This year the event raised £45,000, which is an increase of 171Q/o in revenue compared to 2022.
The Spanish Ambassador's residence in London h05ted an exquisite Charity Evening of music, fo(rf and
fundraising, featuring the gracious soprano Ainhoa Arteta and th¢ ingenious chef Quique Dacosta, with
gener0115 5ponsor5hip froin market￿ess. During the event, CRtS highlighi¢d Prof¢ssor Persis Amrolia.
who discussed the pioneering CAR-T cell re5¢arch for Childhood leukemia funded by CRtS. The event
successfully raised an impressive £400,(K)O.
Ftindrttising ttclivilses (corporLylg)
In February 2023, we relaunched our partnership with I￿al restaurdnts to mark World Cancer Day.
Participating r¢staurants added £1 to th¢ final bill with customer consent. This initiative was part of our
CRIS Canc¢r Awar¢n¢ss Month campaign, dnd succ¢ssfully raised £13.0(K).
CRIS organised the 'On Ya Bike static bike challenge. in collabordtion with Barclays in iheir London and
Paris offJ¢es. This event raised awareness for two CRtS paedialric brain tU￿Or piojec15 at the Institute or
Cancer Research IICRI in London dnd the Gu5tave Rous5y Institute in Paris. Eleven te￿￿$ compel¢d in
categories such as 'longest distance cover¢d,
most funds raised," and "fasiesi rider." This engaging
initiative raIsed £47,000 for CRts.
During 2023, we raised £242,200 in donations from our lorLg-temi Corporate partners. including AKO
Capita], Barclays, General Atlanti¢, D'Angelin, and Goldman Sachs. As part of coq)orate donarions. CRIS
r¢ceived a £50,000 donation from ICE Futures Europe. Coinpanies such as Janus Henderson, VISA, and
Microsoft malch¢d ¢mploy¢¢ donation5 to CRIS.
Single donolion3
In 2023. we raised £49.094 in individual donations that are given 2s regular paym¢nts or on¢-off amount&
Gift Aid
Th¢ total Gift Aid to b¢ ¢laim¢d from HMRC in 2023 was around £150,000.
ENV45728537-2320-EEM4g64-CCDB
0710812024 09.'W AM UTC

CRIS CANCER FOUNDATION
REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2023
FUNDING CANCER RESEARCH PROJECTS
CRIS Cancer Foundation continues io sponsor cutting-edge research projccts through ils
partnersh￿pS with the Instifute of Cancer Rcsearch (ICR), Oxford University, and GOSH in the UK
as well &% the European oon50rtium"Fight Kids Cancer"
In 2023, CRIS donated £1,713,146 to charitable activiiies. which represents an Ine￿ast of 17V/o Yoy
v¢r5us 2022. This included..
Fsght Kids Cancer IFKC).. in 2023 CIUS UK donal¢d £467,130 to the Pan.Euro￿an
consortiuin FKC that focuses IFn raising fvnds for research into different types of paediatric
an¢er.
Oxford Univeisily, Pos[doc￿ra1 Research Fellowships.. Togeth¢r with th¢ US Prostate
Cancer Foundaiion. the most prestigious prosiate cancer research foundation in the world,
CRIS has cts-financed 2 researche15 through th¢ Young Investigator Awards. The total
donation paid by CRtS in 2023 w&% £lOO.000.
The lininunoth¢rapy Project at the Institute of Cancer Research IICRI". This piojeci
includes a group ¢OOTdiDal¢d by Dr. Astero KlainpatsL with funding of £367,225. Cancer
immunotherapy, which involves treatsnents thai hamess the body's own iinmune system lo
destroy tumours. represents one of the most promising and rapidly advancing atEas in
caDc£r r¢s¢ar¢h and tr¢atin¢nl.
Childhood Brain Cancer Project ai the Enstirute of Cancel Reseatch IICRI. Coordinat¢d
by Professor Chris Jones and funded with £115.173. this initiative is part of CIUS'S
ongoing support for the Children's Brain Tumour Project. CRtS's Involv¢￿ent began in
November 2015 when it eniered into a Deed of Gift with th¢ ICR. Since that date. CRIS
UK has invesied a total of £700.(X)O in this ciilical resedrch.
Cenire foi Tianslational Imrnunotherapy.. Based al the ICR and led by Prof. Alan Melcher
and Prof. Keviu Hartington. CRIS has invested £142,668 thi5 year, (bringing the total
amount jllVeSted since 2021 to £424.0001. Moying fon¥rf we have committed lo invest
an addilional £755.852 over the nexl three years, to continue to SUPF<)rt the vital research
work al thi5 cenlre.
Multipl¢ Myeloma project led by Dr Charlotte Pawlyn at the ICR. This two-year
agreement amounts lo a yearly payment of £55,950 which began in 2022.
CRIS (togeiher with Cancer Research UK) is co-fi]nding a revolutionary clinical trial led
by Prof. Sarah Blagden. from the University of Oxford. This trial has been designed for
patients who have received an early diagnosis of lung cancer and have received surgery to
remove their tuinourls). These patients have & high risk of relapse or dcv¢loping new lung
miouts. CRIS invested £250,000 in 2023.
Plediatric Leukemia Proje¢1 ai GOSH (New for 2023).. Dr. Persis Amrolia's team will
treat 12 patients with dual CAR-T cells. These specialised CAR.T cells have been
modified to reco￿lse two different tumour molecules. rather than just one. This dual-
targcting approach ensures that if a tumour manages to conceal one type of molecule. the
therapy can still be effective against the other. In 2023. CRIS invested £215.(M)O in rhi$
innovative project.
ENV45728537-232O-EEAA4￿ccDB
0710812024 09."00 AM UTC

CRIS CALYCER FOUNDATION
REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2023
Financial review
The results for the period are as set oui on page 10 and show that the charity achieved a very succcssful
fvndraising periLKI in 2023. Total income for ihe year ended 31 Deceinber 2023 amount¢d to £3,010,944
(2022.. £1.790,5911 of which £2,036.264 {2022.. £1,573,401) was raised froin ¢v¢nts. After fundrnising costs
of £331,230 (2022.. £160,366), the net funds raised froin ¢v¢nts for the period were £1,705,034 (2022..
£1.413,0351.
During th¢ perilxi, CRIS inad¢ total donations of £1,713,14612022.. £1,468,154) io the Lnslitute of Cancer
R¢s¢arch (ICRI, Oxford, GOSH and Fight Kids Cancer. Overall. the lolal Surplus was £769,125 12022..
£12,139).
Ai the financial period end. together with ieserves broiight forward of £2,212,355 12022.. £2,200,216), the
total funds. all of which are untestticted, available for cary forward amounted lo £2.981.480 {2022..
£2,212,35SI.
Investment poiiey perforThance
There are no restriction5 on the charity's poweT to invest and the current policy Rs to invest short tenn
deposits with the charity'5 bankers.
Reserve5 policy and going concern
The charity'5 policy is to maintain a sufficient level of ieserves to enable the operating activities of the
charity to continue. With the excepiion of annual governdnce costs. whjch ale estimated at £7,500, the
amount of funds required to operdte the charity is not significant at an esliinated amount of £78,000 per
annum. The trustees do noi charge the charity for the seryices Ihey provIde and tlie evenls that are held are
tnvariably s¢lf-funding evenis. CRtS is accordingly in an enviable p05ltion as the risk of it not being able to
operaie as a going concern due to lack of funds is considered to be remote.
Structure. governance and management
CRIS Cancer Foundaiion ICRtSI was incorporated on 14 January 2011 a5 a charitable Company which is
limited by guarantee with no share Capital and governed by its Articles of Association. CRIS was registered
as a charity with ihe Charity Commission for England and Wale5 on 2 February 2011. The liability of each
member in rhe eveni of winding up is limited to a maxiilluin of £1.
In accordance wilh the gtsveming document. there shall be not less than three directors at any one time. The
directors. who are also the charity Inlslees, are nOrn￿llY elected by the Ineinbers of the company In a
general tneeting.
Truste¢s are appointed on the basis of specific skills and knowledge to enable them to make a eonlribution
lo the management of the chariry. In order foi itustees to undertak¢ S￿h rcspon5ibilities, appropriate
Charity Commission publications, in particular the booklet 'The Essential Trustees.. What you need to
know, is given to each trwstee ￿ part of their induction prnee￿.
Risk management
The iNsiees have reviewed the major and financial risks that impact on the work of the charity and
undenake reviews of risk management on a continuing basis. The syst¢ms that have been established enable
the irusiees to review and take necessary slep5 to les5¢n th¢s¢ risk&
Future development
The trustees are working to increase the funds received from corporates. Whilst also looking 10 add n¢w
ompanies to the February campaign, we are aiming to explore additional funds coming from eoinpani¢s
whether it is via their inalching scheme, by hosiing an employee event in their pr¢inis¢s or by bcing able to
receiving funds ftom smaller financial institutions Ihai would lik¢ io d¢di¢ai¢ part of th¢iT profits to ESG.
We will also continue 10 consolidaie our Major Donor effort as il is our main source of funds and what is
currently financing all our commitments wirh the different research instifutions.
ENV45728537-232o-EEAA4￿CcD8
0710812024 09.'00 AM UTC

CRJS CANCER FOUNDATION
REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2023
Referen£e and administrative information
Directorsryru5tees
Marta Brime- Chaimjan
icola Louise Ainor050
Maria Dolores Manleiola {aka Lola Manlerolal
Fernando Delgado-Nevares
Eleonora Geraldine Creaturo
Diego Megia
Alvaro Portanet
Snigdha Singh
Josefa Diaz Mercado
Chn'siopher Ciauri
Ana De Paz
Treasurer
Ana De Paz
Company number
7493363
Re8jStered charity number
1140193
Registered office
Quadrant House
Elw IYW
Floor 6. 4 Thomas More Square. London
Place of business
Second floor office. 3A Hatnngton road. South Ken5inston,
London SW7 3ES
Auditors
UHY Hack¢r Young, Quadrant House. 4 Thomas Mote Square,
London Elw IYW
Bankers
Virgin Monry, 177 Bothwell Street, Glasgow G2 7ER
Solicitors
Bates Wells & Braithwaile London LLP
2-6 Cannon St￿et. London EC4M 6YH
ENV45728537-232c￿EEAA4wcCDB
07108r2024 09..￿ AM UTC

CRIS CANCER FOUNDATION
REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2023
Responsibilities of the Board
The Trustees who are also the directors of the Foundation for the piirposes of company law are responsible
for preparing the TrLLStees' Report and the firwiciai statements in accordance with applicable law and
United Kingdorn Accounting Standards (United Kingdoin Generally ACcep￿d Accounting Practiccl.
Company law r¢quir¢s the Trustees to prepare financial statement5 for each financial year whi¢h give a ttue
and fair vicw of the state of affairs of the Foundaiion and the incoming resources and application of
rcsourc¢s, including the income and expenditure. of the Foundation for that period.
In preparing these finatt¢ial statements, the Tru51ees are required to.
select suitable accounting polici¢s and then apply them consisienrly.
observe the meth(MJs and principles in ihe Chatiiies SORP;
make judgements and estimate5 that are reasonabl¢ and pjudent.
stale whether applicable UK Ac¢ounting Standards have been followed. subject to any tnaterial
departures disclosed and explained in ihe accounts.. and
prepare the financial siaternents on the going concem basis unless it is inappropriate ro presume
that the Foundaiion will continue in business.
The Trnsiees are r¢5POll5ible for keeping proper accounting records ihai disclose with reasonable accurdey
ai any time rhe financial p05ilion of the Foundation and enable the Trnsiees io ensttie thai the financial
stateinen15 coinply with the Companies Act 2006. The Twstees are also responsible for safeguarding the
assets of the Foundation 4￿d hence for taking reasonable steps for ihe prevention and deieeiion of fraud and
other irregularities.
This report ha5 b¢¢n prepared in accordance with the special provisions relaiing lo small companie$ within
Part 15 of th¢ Componies Act 2006.
By OTdeT of the Bo4Td:
Marta Brime- Trustee
Chairman of Board of Trustees
Date.. 30 July 2024
ENV45728537-2320-EEAA4964-CCDB
0710812024 09..00 UTC

UHY Hacker Young LLP
C)tsadrani House
4 Thomas More Square
London EIW
Hackeryoung
Chaitefed Accountants
INDEPENDENT AUDITOILS, REPORT TO THE MEMBERS AND TRUSTEES OF CRIS CANCER
FOUNDATION FOR THE YEAR ENDED 31 DECEMBER 2023
Opinlon
We have audited the fmaTLciai statements of CRIS Canc¢r Foundation (the 'Charity') for the year ended 31
DecembeT 2023 which comprise the Ststement of Financial Activities. the Balance Sheet, the Cash Flow
State￿ent and the nores io Ihe flDan¢ial statements, including significant accounting w)licies. The financial
ieporting framework Ihai has been applied in their preparaiion is applicable law and United Kittgdom
Accounting Standards. in¢luding Fin0￿claI Reporting Standard 102 'The Financial Reporting Sthndard
applicable in the UK and Republic of Ireland (United Kingdom Generally A¢¢¢pted Accounting Practice),.
In our opinion the financial statements..
give a true and fair view of th¢ stale of the Charity's affairs a5 at 31 December 2023 and of ils in¢oming
resources and application of resouT¢es, for the yeaT then ended,.
have been properly prepared in accordance with United Kingdom Generally Accepted Accounting
Practice,. atjd
have been prepared in accordance with ihe rffjuiremenis of the Companies Act 2006.
Basis for opinion
We condllcied OUT audit in accordance with International Standards on Auditjng (UK} IISA5 IUKI) and
applicable law. Our responsibilitie5 under Ih05e standards are further descnbed in th¢ Auditorfs responsibilities
for the audit of the financial sralements Section of our report. We are independent of the Charity in accordance
with the ethical requirements Ihal are relevant to our audii of the financial statements in the UK. including rhe
FRC'S Ethtcal Standard. and we have fulfilled our other ethical r¢sponsibiliiies in accordance with tlwe
requiremen15. We believe that the audii evidence we have obtained is sufficieni and appropriate to provide a
basis for our opinion.
Conclusions relating to going eoneern
Itl auditing the f￿ancIal stst¢ments, we have ￿ncluded that the trustee5' U5¢ of the going concern basis of
accouniing in Ihe prepardtiort of the financial statemcllls is appropriate.
Based on the woik we have perfornied. we have not ideniifjed any Jnaterial uncertainties Telatillg lo event5 or
conditiot)s tha( individually or collectively. may c&8t significant th)ubt on the Chatity's ability to continue as a
going ¢oncem foi a peiiod of at least 12 ￿O￿th5 fr0]n when the financial siatements are authorised for issue.
OUT respon5ibililies and the responsibilities of the trustees with Tespect to going concern are descriF*d in ihe
relevani 5ecrions of this report.
Other information
The other infonna¢ion ¢onwris¢s the inforniation iticluded in the Truslees, Report. Our opinion ON the fllrdncial
statements does not cover the other informaiion and, except io th¢ extent otherwise explicitly stated in our repo
we do not express ally fomi of assurance conclusiotj thereon.
In connection with our audit of the financial statements, our responsibility is to read the other iofomiation and. in
doing so. consider whether ihe orher informaiion is mateiially inconsistent wilh the financial siatements OT our
knowledge obtained in the audii or oihetwise appears to be mateiially ]ni5Stated. If we ideniify su¢h material
inconsisiencics or apparent material misstatemenls, we are Tequired to determine whether there is a maieTial
misstatemeni in the financial statetnents tsr a material mis51al¢menr of the other information. If, bastd on the
WOTk we have perfoT]ned, we conclude that there is a marerial misstatement of this other information, we are
required to report ihat fact. We have noihing io report in this regard.
ENV45728537-2320-EEAA4WCCDB
0710812024 09".00 AM UTC

UHY Hacker Youtvj LLP
Quèdrani House
4 Thoina5 Mofe Squaie
LondonEIW
Hackeryoung
Chartered AccourTrtant5
11SDEPENDEP4T AUDITORS, REPORT TO THE MI EMBERS AND TRUSTEES OF CRIS CANCER
FOUNDAT10Tr4 FOR THE YEAR ENDED 31 DECEMBER 2023
Opinion$ ort other mitters prescribed by the Comp9nies Att 2006
In our opinion, based on Ihe work undertaken in the course of Oilr audii..
the information tsiven in the t￿stees, rewn for the fituncial year for which the financial statements are
prepared is consisient with the financial statements: and
the trustees, report have been prepared in accordance wirh applicabl¢ legal Tequirem¢nts.
Matter$ ON whlth we are requlrej to report by ex¢eptlon
In the Iighi of the knowledge and understanding of the Charity and its environment obLqined in the course of our
audit. we have not idetttified material misstsiements in the TNstees' Rep)rt {whi¢b In￿rporat¢S the directors.
report}.
We have noihing to report in respect of the following mallers in relation to which the Companies Act 2006
requires us 10 report 10 you if, in our opinion..
adequate and ptopei a¢¢ouniing iecords have not been kept, or reiums adequate for out audit have not
beerl received frotn branches rK>t V151t¢d by us. OT
the financial siaiements are not in agreement with the accounting records and returns,. or
certain disclosures of truste￿. remuneration specifled by law are not made. or
we have not receiv￿ all the itLfoTtnatitsn and eXpla[￿tIonS we iequite foi OUT audit. or
the tTUStees were not entitled to prepare the financial statements in accordance with the small cotnpanies
regime and take advaTLta8c of the Small companie5, ex¢mption5 in preparing the strdtegic report.
Re$pon$ibilitie$ of trustees
As explained more ￿]lY in th¢ twste¢s' r¢sponsibilities st&t¢ment s¢t out on pag¢ 6, Ihe ttusiees. who are also the
dire¢¢ois of the charitable company foi ihe purpose of Company law, are responsible for the preparation of the
rinancial 5tttemen15 whi¢h give a true and fair view, and for such inietnal Control ds the twstees detem)Ine Is
necessary lo enable the preparation of financial stat¢￿entS that are free from material rnis5tatement. whether due
to fraud or error.
preparing the fiDaT2ciai statements, the trustees are resptsnsible for &8se5sing the Charity's ability to continue as
a going concern, di5c105ing a5 appli¢able, tttatter5 related to going concetn und using the going concetn basis of
accounting unless (he iruslees either intend to liquidate the Charity or to cease operations, or h&ve no realistic
aliernalive but 10 do so.
Audltor's responslbllltlts for the 4udlt of the fingnclgl statements
Our objectives ate to obtain reasonable assurance about whether the financial statements as a whole are free from
material mi5btatcment, whether due to fraud or error, and 10 issue an alldiior's report thai Includes our opirtiort.
Reasonable assurance 15 a high level of assurance, but is ￿t a guanntee that an audit Conducted in accordance
with ISAS (UK) will always detect a material misstatement when it exists. Mis5talements can arise from fraud or
error and are considered maierial if, individually or in the aggregate, they could reasonably Ee expected to
influence the economic decisioThs of users taken on Ihe basis of Ihese fJnan¢ial sthiements.
Irregularities, including frnud, ar¢ irtstan¢¢s of non-compliartce with laws atyl re8ulations. W¢ design proc¢dures
in line with our responsibilities, outlined above. to detect maieiial misstaiements in respect of i￿egUlar1tie$,
including frnL￿. The extent to which our procedures are upable of detecting itregulatities. including fraud, is
detailed below.
Based on our understanding of the Charity and the industry in which it operate5. we identified that the principal
nsks of non-eomplIan¢e with laws and regulations relaied 10 the acts by the Chariiy, which were conirary to
applicable laws and regulations including fraud. and we coosidered the extent to which non-¢ompliance might
have a material effect on the financial statements. We also considered those laws and regulations thai have a
direct impact on the preparntion of the financial statements buch as the Companies A¢1 2006. We evaluaied
management's iDcentive5 and opportUTLities for fraudulent ttwiipulation of the fjnancial 5talem¢nt5 lillcluding ihe
risk ofoverride of contro151, and detennined that the principal risks were related to inflated income.
ENV4S728S37-232(>EEAA4WCCDB
07/08r2￿24 09'.00 AM UTC

UHY Hacker Young LLP
Quadrant House
4 Thomas More Squère
London EIW IWN
Hackeryoung
Chartered Accountants
INDEPENDETrrr ALTDITORS, REPORT TO THE MEMBERS AYD TRUSTEES OF CRIS CANCER
FOUNDATION FOR THE YEAR EYDED 31 DECEMBER 2023
Audit procedures perfornied included.. review of the flnancial ststemeni disclosures to underlying SUPPOfling
documeniaiion, enqiiiries of manageinent and iesiing of journals 2nd ev21uaiing whether there wa5 evidence of
bias by the Tnjstees that represented a nsk of matuial misstatement due lo fraud.
There are inherent limitations in the audit proceduTes described above and the further removed non-compliance
with law5 and regulation5 js from the even15 and transaciions reflected in the fjnancial siaiemenis. the less likely
we would become aware of it. Also, the risk of not detecting a material misstatemeni due to fraud is higher Ihan
the risk of not detecting one resulting from error. as fraud may involve deliberate concealment by, foi example,
forgery OT Intentional misr¢pt¢seniaiions, or through ¢ollu¥ion.
A further description of our responsibilities for the audit of the financial statements is located on the Financial
Reportitig Council's website ai.. www.frc.0rg.uklaudiiorsres￿nSlbI1itles. This d¢scription forn]s part of our
auditor's iepoti.
Us¢ of our report
This report is made solely to the Charity's membeTS. as a body, in a¢¢ordance with Chaprer 3 of Part 16 of the
Companies Aci 2006. Our audit work has been undertaken so that w¢ tni¥ht State to the Charity's ]nembers those
maiteis we are required to state 10 them in an audit015' report and for no other pu￿0￿. To the fullesr exienl
permitted by law, we do not accept or assume responsibility lo anyone oiher than the Charity atld its member5 a5
a body. foi OUT audit work. foi this repoTL or for the opinion5 we have foTmed.
Rachel Chlm {Senlor Statutory Audltorl
UHY H#¢kerYoung
Statutory Audiior
Quadrant House
4 Thoma5 More Square
London Elw IYW
Dat¢.. 07108/2024
ENV45728537-2320-EEAA4964-CCDB
0710812024 09'.fKJ AM UTC

CRtS CANCER FOUNDATION
STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 DECEMBER 2023
Unrestricted Reslricted
funds
funds
2023
2023
Total Unrestritled Rcstrl¢ted
fu]Jd$
funds
2022
Total
funds
2022
2023
2022
Notes
Incoming resources
Income from..
Donations #nd Icgacies
-Oih¢r trading activities
-Inv¢stm¢nts
955,291
2.0362(A
19,389
955,291
2.036,264
19,389
210,978
1.573,401
6,212
210.978
1,573.401
6,212
Total incorning resources
3,010,944
3.010,944
1,790,591
1,790.591
Expertdlture on=
Raising funds..
Fundraising events
439,432
439.432
239,826
239.826
Charltable activili¢s'.
Donariorts made
1.802.381
1,802,387
1,538,626
1,538.626
Total
2,241,819
2,241,819
1.778.452
1.778.452
Net Movement in funds
769,125
769.125
12.139
12.139
Reconclllatlon of fund$
Total funds brought forwaTd
2.212,355
2,212,355
2,200,216
2,200.216
Total fund5 eY4rrled forw8rd
2.981.480
2.981,480
2.212.355
2,212,355
The results for the period are derived froin continuing op¢rdtion5.
There were no ￿08n[s¢d gains or losses, other than those passing through the statement of financial
activiti¢s.
10
ENV45728537-2321>EEAA4&34-CCOB
0710812024 09.'(KI AM UTC

CRIS CANCER FOUNDATION
BALANCE SHEET
AS AT 31 DECEMBER 2023
31 December
2023
31 December
2022
Note5
Fixed assets
Tangible assets
Inve51ments
3.437
199,998
8,595
203,435
8,595
Current asset$
Debtor5
Cash at bank
546,255
2,260,864
453.416
1,824.818
2.807,119
2.278,234
Creditors: Amounts falling due
within one year
{29,074}
{74.4741
Net current assets
2.778,045
2,203,760
Total assets less current liabilities
2.981,480
2,212,355
Nel assets
2,981,480
2,212,355
Funds of the charity..
Unre5tricled fund5
Restricted funds
2,981,480
2,212,355
2,981,480
2,212,355
Approved by the Board and auihorised for issue on 30 July 2024
Marta Brime- Direetor
Company Number: 7493363
ENV45728537-2321>EEAA4964-CCDB
0710812024 09.'00 AM UTC

CRIS CANCER FOUNDATION
CASH FLOW STATEMENT
AS AT 31 DECEMBER 2023
31 De¢ 2023
31 Dec 2022
Notes
Operating & iDV¢$ting #ctivities
Receipts of int¢r￿¢
Receipts of other cash
Payment of chariiable grants
Payment of expenses
Depreciation charge of tangibl¢ assets
Purchage of investments
19,389
2,893,218
(1,713,146)
(568,575)
5.158
{199,998)
6,212
1,639,202
{1,468,150)
{311,251}
5,157
Increase/{Decreasel in cash from
operating & investing activities
{A)
436,046
(128,830)
Increase/{Decrease} in cash
(B)
436,046
{128,830)
(A) Reeonciliation of change5 in resources to net cash
inflow from operating & investing activities
2023
2022
Depreciation of tangibl¢ fixed assets
Purchase of investments
Net incoming resources
Increase in debtors
Increasel {Decrease) in creditors
5,158
(199,998)
769,125
(92,839)
(45,400)
5,157
12,139
(152.674)
6.548
436,046
{128,830)
(B) Analysis of ehanges in ea5h b3lan¢e5 during the year
2023
1022
Cash ai beginning of penod
Cash at end of period
1,824,818
2,260.864
1,953,648
1,824,818
Increas&l {Decrease) in cash
436.046
(128,830)
12

CRIS CANCER FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023
Accountlll8 policie5
Company information
Cris Canc¢r Foundation is a private coinpany limited by guarantee incorporated in England and
Walcs. Th¢ registered office is Quadrant House, Floor 6, 4 Thomas More Square, London, Elw
iyw.
Aeeounting eonventio
These financial sraiemenis have been plepared in accordanc¢ with Accounting and Reporting by
Chariiies.. Siatemeni of Recommended Practice applicable to charities preparing their accounts in
accordance with th¢ Financial R¢porting Stsndard applicable in the UK and Republic of Ireland
IChaTiti¢5 SORP - FRS 102), The Financial Reporting Siattdard applicable in the UK and Republi¢
of ITel8nd" (FRS 102) and the Charities Act 2011 and the requirements of the Cotnpanie5 Act 2006
as applicable to companies subject to the small companies regime.
The financial siatemenis ale prepared Ln sterling, which is the functional currency of the company.
Monetary amounis in these finaucial statements ar¢ Tound¢d to the nearest £.
CRIS Cancer Foundaiion meets tlie defjnition of a public ¢ntity undcr FRS 102. The financial
staiemenis have been prepared on the historical cost ¢onv¢ntion and th¢ principal accounting policies
adopted are set our below.
F￿ThdS Strueture
Restricted funds are fi]nds which to be used in accordance with specific restriciions imposed by
the donor. Unrestricted funds are fvnds which are used in accordance with the charitable objects ar
the discretion of the trustees.
Incorning resources
Incoming resources are accrued and included in th¢ SOFA when the charity is etttiiled to the income,
the receipt can be quantified and is probable and deferred when they relate to future accounting
periods. Gift Aid receivable is includ¢d in income when ihere is a valid declaration from the donor
and the donatsons has b¢cn rcceiv¢d.
The following policies apply to the following specific categories of inc0￿e frotn fi]ndraising ev¢nts.'
Incomefrom Annual Gala Dinner
Ticket. auciion and spon50r5hip income ftom the Annual Gala Dinner is disclosed under other
trading activities and recognised when r¢¢eivable.
Incon7efrompersorRal challertge and oÉherfiindraisirig evertls
Marathon, bike challenge and other fundraising income. which are In substance donat%ons, are
disclosed as donations when receivable.
Investment income
Investtncni income represented by interest on monies held on dep051t is includ¢d in SOFA when
receivable by the charity.
13
ENV45728537-2320-EEAA4964-CCD8
0710812024 09..00 UTC

CRIS CANCER FOUIYDATION
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023
Aeeounting polieies (continued)
Resources expended and irrecoverable VAT
Liabilities ore recognised as resources expended as soon as there is a legal or constNciive obligation
coininilting the charity to the expenditure. All expenditure is accounted for on an accruals basis and
hos been classified under headings that aggregate all costs related io the ca*gory.
Irrecoverable VAT is charged agaittst the category of resources expended for whi¢h it was in¢urr¢d.
Going cfrneern
The accol￿ts have been prepared under the going concern basi5 a5 th¢ trustccs are of the opinion that
the charity's forthcoming events. including the annual Chdrity Gala Dinncr, plus sotne reserve
funds will cover minimal operational cosis and enable the eharity lo mcet its obj¢ctiv¢s of funding
eancer ￿SearCh.
T4ngRble fixed assets
Tangible fixed assets are staled at cost {or deemed cosi) 01 valuaiion less accumulated depreciation
and accumulated impaim)ent losses. Cost ineludes costs diteeily attribu￿b]e to inaking the asset
capable of operating as intended.
Depreciation is provided on all iangible fixed assets. ai rates calculated to write off the c05t, less
estiinated residual value, of each asset on a sysietnatic ba515 over it5 expected useful life as follows..
Fixtures and fittings
200/0 on cost
Investments
Progrnmme-related Investments are made to ￿llher to charitable p￿￿ose$ of the ¢harity. Th¢y a
held at cost less any provision for impairnient.
Financial instruments
The company has elected to apply the provisions of Section I I 'Basic Fitwicial Instruments, as
Section 12 '0ther Financial Instruments Issues, of FRS 102 to ail of its financial instruments.
Financial insttuments are Tecognised in the cornpany's Statement of financial position wh¢n th¢
Cotnpany becomes party to the contractual provision5 of thc instnlment.
Financial ass¢ts and liabilili¢s are offset, with the nei amounts presented in the financial statements.
when there is a legally enforceable right to set off the recognised amounis and there is an intention to
setile on a net basis or to realise the asset and settle the liability simulianeously.
Basic financial asset5
Basic financial asscts, which include debtors and cash and bank balances. a￿ initially measured at
transaction price including transaction costs and are subsequenily Ca￿led at ￿nOrtised cost using the
effeciive Inierest method unless ihe arrangement constitutes a financin¥ transaction, where the
transaction is measured at the present value of the future receipts discounted at a mark¢t rate of
interest. Financial assets classifjed ds receivable within one year are not amortised.
14
ENV45728537-2320-EEAA4964-CCDB
0710812024 09..00 AM UTC

CRtS CANCER FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023
Aeeounting policies (continued)
Impairment of fjnancial assets
Financial ass¢ls. oth¢r than thos¢ h¢ld at fair value through profit and loss. are assessed for indicaiors
of impaimicnt at cach rcporting ¢nd datc.
Financial assets are impaired where ihere is objective evidence that, as a result of one or inore event5
that occurred after the initial reCo￿ltI0￿ of tlie financial asset, the estiinated future cash flows have
been affecred. If an asser is impaired. the impairment 1055 IS the difference between the carying
amount and the present value of the estimated cash flow5 discounted at the as5et'5 original effective
interest rate. The impairment loss is recognised in profjl or loss.
If there is a decrease in the iinpairment10ss arising froin an ev¢nt o¢curying after the impaimient was
recognised, the impairnienl is r¢v¢rs¢d. Th¢ reversal is such ihat the current carrying amouni does
not exceed what the carying amount would have been. had the impairnient not previously been
reco￿]sed. The impaim)ent reversal is recognised in profit or loss.
Derecognition of financial wssets
Financial assets are deTecognised only when ihe contractual lights to the cash flows from th¢ asset
expire or are settled. or when the coinpdny transfers Ihe financial asset and substantially all the risks
and rewaids of ownership 10 another entily. oi" sf soine signifjcant risks and rewards of owneTship are
retained bui control of the asset has transfened to another party that is able to s¢ll the asset in its
eniirety to an unrelated ihird party.
Classlt]eatlon orrJn#ncial liabilities
Financial liabilitle5 and equity inslrutnenls are classified accgrding to the substance of the contractual
8￿ngeMentS entered into. An equity instrurnent is any contract that evidences a residual interest in
the assets of the company after deducting all of its liabiliti¢s.
Basic financial liabilitie5
Ba51c financial liabilities. including creditors, bank loans, loans from fellow group companies and
preference shares that are classified as debi, are initially recognised at transaciion price unless the
arrangeinenl constitutes a financing Iransaclton, where the debt instrument is measured ar the preseni
value of the future receipts discounted at a Inarkel rale of interest. Financial liabilities classified as
payable within one year are not amortised.
Debt insttuments are subsequently carried at amortised cost. using the effectiv¢ ini¢f¢st rnte method.
Trade creditors are obligations io pay for goods or services that hav¢ been a¢quired in the ordinary
tourse of business from supplier5. Amoun15 payabl¢ ar¢ classified as CULTent liabilities if paymeni is
due wiihin one year or les5. If not, they are presenl¢d as non-CUTrent liabilities. Trade creditors are
recognised initially at transaction price and 5ubs¢qu¢ntly m¢asur¢d at amortised cost using the
effeetive int¢r¢st Ill¢ih￿.
Derecognition of financial liabilities
FinaD¢ia] liabilities are derecognised when the compamy's contractua] obligations expire or 8Jt
discharged or cancelled.
Operating leases
Rentals payable under operaring leases, including any l¢as¢ in¢¢ntiv¢$ received. are charged to
income on A strttighi lin¢ basis ov¢r th¢ temi of th¢ r¢l¢vant lease.
15
ENV45728537-2320-EEAA4WCCDB
0710812024 09..￿ AM UTC

CRIS CANCER FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECE.MBER 2023
Employees
There was on average 3 employees in the peri(Kl12022.. 2).
Anslysis of staff costs
2023
2022
Salaries and Wages
Social Secunty Costs
Pensions
110,480
6,729
2.538
69,962
2,829
1.645
119,747
74,436
Higher paid st•ff
Th¢ numb¢r of employees whose employee benefits (excluding employer pension costs) exceeded
£60.000 was 112022 01.
No key management petsonnel are remunerated during the year12022.. 01.
Income and endowments
2023
Total
2022
Total
Unrestricted
Restricted
3.1 DonatioThs and legAcie5
Direct gifts from individuals and organisations
Events and other income
291.276
664,015
291,276
664,015
152.646
58,332
955,291
955.291
210,978
3.2 Other trading activitie5
Annual Gala Dinner
2,036,264
2,036264
1,573,401
2,036,264
2,036.264
1.573,401
3.3 Investments
Bank interest
19,389
19,389
6,212
16
ENV45728537-232(>EEAA4WCCD8
0710812024 09".00 AM UTC

1> rqr4QQ
ggg
¢4￿C4*-

CRIS CAYCER FOUNDATION
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBLR 2023
Tanglble flxed &$sets
Fixtures
Total
Fittings
Cost or v*luatlon:
At I january 2023
Additions
25,788
25,788
At 31 December 2023
25.788
25,788
Depreciation..
At l January 2023
Charg¢ for the year
At 31 Deceinber 2023
17,193
5,158
22.351
17,193
5.158
22.351
Net book value..
At 31 December 2023
At 31 December 2022
8,595
8.595
Programme-related inyestrnents (bond):
31 Dec 2023 31 Dec 2022
Inv¢stm¢nts
199,998
During th¢ ycar, thc charity subscribed ro 48.780 seed shares of Infinitopes Limited. a company
registered in England and Walcs. Thc charity made ils investtnent in Infinitopes Limited in order to
fither the Charity's objectives of preventing & diagnosing and of deyeloping new and better treatments
for pcoplc with cancer. The charity will derive ihe benefit of this resCa￿h from InfJnitop¢s over the life
of thc investmeni.
At the balance sheet date, the ￿e0Verable amount is de£med to bc in ¢xcess of the original cost of the
investsnent and as such, no triggers for impainnent have b¢¢n identified.
Debtors: amounts falling due with one y¢4r:
31 Dec 2023 31 Dec 2022
Trade debtors
Prepayments
Othcr dcbtors
534,355
7,400
4.500
354.725
12,898
85.793
546.255
453.416
19
ENV45728537-232¢>EEAA4964-CCDB
0710812024 09."00 AM Lrrc

CIUS CANCER FOUNDATION
NOTES TO THE FINANCIAL STATEMENrs
FOR THE YEAR ENDED 31 DECEMBER 2023
Other creditors: amounts falling due within one year
31 Dec 2023 31 Dec 2022
Other creditors and aCen￿lS
29.074
74,474
Financial instruments
31 Dec 2023 31 Dec 2022
Carying amount of financial assets:
Investments
Debtors
Prepa)rynents
Other debtors
199,998
534,355
7,400
4.5(M)
354,725
12,898
85,793
746,253
453,416
Canying amount of financial liabilities..
Other creth'tors
129,074)
{74,474)
717,179
378,942
10 Operating lease eomrnitments
At the reporting end date, the ¢harity had outstanding commitments for fijture minimum lease
payments under non-cancellable operating l¢as¢s. which fall due as follows..
31 Dec 2023 31 Dee 2022
Within l year
2-5years
10,800
21,600
10,800
EO,800
32,400
11 Analysls of charltable fund$
Bxlance at
l Jan 2023
Incoming
re$ources
Resources
Balanee at
expended 31 Dec 2023
Unrestr2Cted fvnds..
General Funds
2,212,355
3,010,944
(2,241,819)
2,981,480
2,212,355
3,010,944
{2,241,819)
2,981,480
R¢stri¢t¢d funds
Total
2,212,355
3,010,944
12,241,819)
2.981,480
20

CIUS CANCER FOUNDATION
NOTES TO THE FINANCIAL STATEMEYrs
FOR THE YEAR ENDED 31 DECEMBER 2023
IZ An8lysls of net assets between fund$
Unrestricted
fllnd$
Restri¢tsd
funds
Total
31 Dec 2023
Total
31 De£ 2022
Fixed assets
Investments
Debtors
Bank
Creditors
3,437
199,998
546,255
2,260,864
129,074)
3,437
199,998
546,255
2.260,864
(29,074)
8,595
453,416
1,824.818
(74,474)
2,981,480
2,981,480
2,212,355
13 Tru$tees' emoluments
No trust¢¢ or any p¢rson ¢onn¢¢t¢d with a truste¢ has received or is due to rtteive any remuneration or
expenses for the period directly or indirectly from the charity's funds.
14 Related party tr*n$aetlon$
CRIS made donallons of £Nil12022.. £79,447) io Fundacion CRIS de Investigacion para Vencer el
Cancer, a chariiable organisation registered in Spain and related to CRIS by virtue of common
trnstees, Lola Manterola and Diego Megia.
CIUS also made a donation of £Nil (2022.. £5,000) to CRtS Cancer France. a charitable organisation
which is related to CRIS by virtu¢ of Common trustees, Lola Manterola and Diego Megia.
During the period, the trustees made donations to CRIS totalling £353,85012022.. £229,100).
15
Taxation
As a charity, the Foundation is exempt from UK corporation tax io the extent that its in¢ome is appli¢d
to its charitable objects. No liability arose in the year.
16 Capital cornmitmenty
At the year end, the charity is Committed to make donation of £558,328 (2022.. £785,523) to ICR and
other Cancer projects through deeds of gifis.
21